The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial☆
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
(1976) · Medical Entomology and Zoology · Cited by 8,899
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Boehm, G., Racoosin, J. A., Laughren, T. P., & Katz, R. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2088-a · Cited by 1,204
Morosini, P. L., Magliano, L., Brambilla, L., Ugolini, S., & Pioli, R. (2000) · PubMed · Cited by 1,168
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 796
Marder, S. R., Davis, J. M., & Chouinard, G. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1205 · Cited by 759
Correll, C. U., Leucht, S., & Kane, J. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.414 · Cited by 709
Self-citationPeuskens, J. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.166.6.712 · Cited by 551
Bilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538
Leucht, S., Barnes, T. R. E., Kissling, W., Engel, R. R., Correll, C., & Kane, J. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.7.1209 · Cited by 517
Self-citationDelayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected
Agid, O., Kapur, S., Arenovich, T., & Zipursky, R. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.12.1228 · Cited by 408
Daniel, D. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00090-6 · Cited by 377
The functional significance of symptomatology and cognitive function in schizophrenia
Velligan, D. I., Mahurin, R. K., Diamond, P. L., Hazleton, B. C., Eckert, S. L., & Miller, A. L. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00010-8 · Cited by 345
Kasper, S., Lerman, M. N., McQuade, R. D., Saha, A., Carson, W. H., Ali, M., Archibald, D., Ingenito, G., Marcus, R., & Pigott, T. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003651 · Cited by 309
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, C. E., Severe, J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.611 · Cited by 306
ONCE DAILY CONTROLLED VERSUS IMMEDIATE RELEASE OXYBUTYNIN CHLORIDE FOR URGE URINARY INCONTINENCE
ANDERSON, R. U., MOBLEY, D., BLANK, B., SALTZSTEIN, D., SUSSET, J., & BROWN, J. S. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)68810-6 · Cited by 286
Beasley, C. M., Hamilton, S. H., Crawford, A. M., Dellva, M. A., Tollefson, G. D., Tran, P. V., Blin, O., & Beuzen, J.-N. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00392-6 · Cited by 277
Evaluation of Drug-Induced QT Interval Prolongation: Implications for Drug Approval and Labelling
Malik, M., & Camm, A. J. (2001) · Drug Safety · doi:10.2165/00002018-200124050-00001 · Cited by 273
Olanzapine: An Updated Review of its Use in the Management of Schizophrenia
Bhana, N., Foster, R. H., Olney, R., & Plosker, G. L. (2001) · Drugs · doi:10.2165/00003495-200161010-00011 · Cited by 217
Early-Onset Hypothesis of Antipsychotic Drug Action: A Hypothesis Tested, Confirmed and Extended
Leucht, S., Busch, R., Hamann, J., Kissling, W., & Kane, J. M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.02.023 · Cited by 213
Self-citationLieberman, J. A., Koreen, A., Chakos, M., Sheitman, B., Woerner, M. G., Alvir, J. M. J., & Bilder, R. M. (1996) · PubMed · Cited by 211
Csernansky, J. G., & Schuchart, E. K. (2002) · CNS Drugs · doi:10.2165/00023210-200216070-00004 · Cited by 180
Emsley, R. A., Raniwalla, J., Bailey, P. J., & Jones, A. M. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015030-00001 · Cited by 175
Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence
Versi, E. (2000) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(99)00661-4 · Cited by 172
Johnson, D. A. W., Pasterski, G., Ludlow, J. M., Street, K., & Taylor, R. D. W. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb00351.x · Cited by 162
Cognitive function in schizophrenic patients.
Robinson, D. S., Roberts, D. L., Smith, J. M., Stringfellow, J., Kaplita, S., Seminara, J. A., & Marcus, R. N. (1996) · PubMed · Cited by 159
Nasrallah, H. A., & Newcomer, J. W. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000142282.62336.e9 · Cited by 144
Ereshefsky, L., & Mascareñas, C. A. (2003) · PubMed · Cited by 143
Subjective well-being and quality of life under atypical antipsychotic treatment
Karow, A., & Naber, D. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1052-z · Cited by 133
Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.
Newcomer, J. W. (2004) · PubMed · Cited by 132
Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia
Lindström, E., Eriksson, B., Hellgren, A., von Knorring, L., & Eberhard, G. (1995) · Clinical Therapeutics · doi:10.1016/0149-2918(95)80105-7 · Cited by 103
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Thomas, S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., DAVIS, C. E., Severe, J. B., et al. (2006) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.4.4.539 · Cited by 102
Golden, R. N., Nemeroff, C. B., McSorley, P., Pitts, C. D., & Dube, E. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0707 · Cited by 101
Kirby, R. S., Andersen, M. T., Gratzke, P., Dahlstrand, C., & Høye, K. (2001) · British Journal of Urology · doi:10.1046/j.1464-410x.2001.02032.x · Cited by 99
Češková, E., & Švestka, J. (1993) · Pharmacopsychiatry · doi:10.1055/s-2007-1014355 · Cited by 97
Lublin, H., Eberhard, J., & Levander, S. E. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200507000-00001 · Cited by 86
Friedman, J. I., Harvey, P. D., McGurk, S. R., WHITE, L. E., Parrella, M. J., Raykov, T., Coleman, T. M., Adler, D. N., & Davis, K. L. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.8.1388 · Cited by 73
Rate Correction of the QT Interval
Hodges, M. (1997) · Cardiac Electrophysiology Review · doi:10.1023/a:1009933509868 · Cited by 71
Metabolic Effects of Treatment With Atypical Antipsychotics
Kane, J. M., Barrett, E. J., Casey, D. E., Correll, C. U., Gelenberg, A. J., Klein, S., & Newcomer, J. W. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1102 · Cited by 68
Self-citationCognitive Factors in Schizophrenia: Causes, Impact, and Treatment
Meltzer, H. Y. (2004) · CNS Spectrums · doi:10.1017/s1092852900025098 · Cited by 54
Möller, H. ‐., Gagiano, C. A., Addington, D. E., von Knorring, L., Torres-Planks, J. F., & Gaussarès, C. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199805000-00001 · Cited by 51
Karlsson, P., Dencker, E., NYBERG, S., Mannaert, E., Boom, S., Talluri, K., Rossenu, S., Eriksson, B., Eerdekens, M., & Farde, L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.12.265 · Cited by 37
Self-citationThe continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment.
Gerlach, J. (1999) · PubMed · Cited by 36
Hwang, T., Lee, S.-M., Sun, H., Lin, H.-N., Tsai, S., Lee, Y.-C., & Chen, Y.-S. (2003) · PubMed · Cited by 34
Keene, M. S., Eaddy, M. T., Nelson, W. W., & Sarnes, M. W. (2005) · PubMed · Cited by 27
Evaluating the Economic Consequences of Early Antidepressant Treatment Discontinuation
Sheehan, D. V., Eaddy, M. T., Sarnes, M. W., Vishalpura, T., & Regan, T. S. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000140999.45053.07 · Cited by 27
Vermeir, M., Boom, S., Naessens, I., Talluri, K., Eerdekens, M., & Hargarter, L. (2007) · Pharmacopsychiatry · doi:10.1055/s-2007-991778 · Cited by 18
Self-citationKramer, M. L., Hargarter, L., Kushner, S. F., Sherr, J. D., Vijapurkar, U., Lim, P., & Eerdekens, M. (2007) · Pharmacopsychiatry · doi:10.1055/s-2007-991776 · Cited by 6
Self-citation
Cited by
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490
Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method
Leucht, S., Samara, M., Heres, S., Patel, M. X., Woods, S. W., & Davis, J. M. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu001 · Cited by 372
Peuskens, J., Pani, L., Detraux, J., & De Hert, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0157-3 · Cited by 350
Metadata
- Authors
- KANE, J., CANAS, F., KRAMER, M., FORD, L., GASSMANNMAYER, C., LIM, P., & EERDEKENS, M.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2007-02
- Volume
- 90
- Issue
- 1-3
- Pages
- 147-161
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2131658797
- Cited by
- 296
- References
- 50
- FWCI
- 14.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.